Charles River Laboratories International, Inc. (CRL), based in Wilmington, Massachusetts, has a market capitalization of approximately $14.3 billion. The company is a global contract research organization that supports pharmaceutical, biotechnology, and medical device companies. It provides research, drug discovery, safety assessment, microbial solutions, and biologics services to help develop medicines and therapies.
Shares of this leading contract research organization have considerably outperformed the broader market over the past year. CRL has advanced 81.4% over this period, while the broader S&P 500 Index ($SPX) has advanced 18.7%. In 2026, CRL has also continued to outperform, climbing 49.2%, compared with the index’s 12.2% gain over the same period.
